Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial

Author(s): Giulia Malaguarnera, Vito Emanuele Catania*, Gaetano Bertino, Laura Maria Chisari, Maria Castorina, Claudia Bonfiglio, Omar Cauli and Michele Malaguarnera

Volume 28, Issue 38, 2022

Published on: 25 October, 2022

Page: [3158 - 3166] Pages: 9

DOI: 10.2174/1381612828666220830092815

Price: $65

Abstract

Background: Ageing is characterized by a gradual decline in body function, representing the clinical situation called "frailty". Prefrailty is the intermediate stage between frailty and robust condition. L-carnitine (LC) plays an important role in energy production from long-chain fatty acids in mitochondria, and its serum level is lower in prefrail and frail subjects.

Objective: This study aims to evaluate the effect of Acetyl-L-carnitine (ALCAR) in pre-frail older patients.

Methods: We scheduled 3 months of treatment and then 3 months of follow-up. A total of 92 subjects were selected from May, 2009 to July, 2017, in a randomized, observational, double-blind, placebo-controlled study. We scheduled 3 months of treatment and then 3 months of follow-up. ALCAR (oral 1.5 g/bis in die - BID) or placebo groups were used.

Results: After the treatment, only the treated group displayed a decrease in C reactive protein (CRP) p < 0.001 and an increase in serum-free carnitine and acetylcarnitine (p < 0.05) in Mini-Mental state (MMSE) p < 0.0001 and 6-walking distance (p < 0.0001); ALCAR group vs. placebo group showed a decrease in HDL cholesterol and CRP (p < 0.01), an increase in MMSE score (p < 0.001) and in the 6-walking distance (p < 0.001).

Conclusions: ALCAR treatment delays the incidence and severity of onset of degenerative disorders of the elderly in prefrail subjects with improvement in memory and cognitive processes.

Keywords: Carnitine, cognitive impairment, motor impairment, elderly, aging, Acetyl-L-Carnitine, Frailty, Prefrailty.

« Previous Next »
[1]
Fried, L.P.; Young, Y.; Rubin, G.; Bandeen-Roche, K. Self-reported preclinical disability identifies older women with early declines in performance and early disease. J. Clin. Epidemiol., 2001, 54(9), 889-901.
[http://dx.doi.org/10.1016/S0895-4356(01)00357-2] [PMID: 11520648]
[2]
Manton, K.G.; Gu, X. Changes in the prevalence of chronic disability in the United States black and nonblack population above age 65 from 1982 to 1999. Proc. Natl. Acad. Sci. USA, 1999, 98(11), 6354-6359.
[http://dx.doi.org/10.1073/pnas.111152298]
[3]
Kojima, G. Frailty as a predictor of disabilities among community-dwelling older people: A systematic review and meta-analysis. Disabil. Rehabil., 2017, 39(19), 1897-1908.
[http://dx.doi.org/10.1080/09638288.2016.1212282] [PMID: 27558741]
[4]
Lin, H.S.; Watts, J.N.; Peel, N.M.; Hubbard, R.E. Frailty and post-operative outcomes in older surgical patients: A systematic review. BMC Geriatr., 2016, 16(1), 157.
[http://dx.doi.org/10.1186/s12877-016-0329-8] [PMID: 27580947]
[5]
Llansola, M.; Montoliu, C.; Agusti, A. Interplay between glutamatergic and GABAergic neurotransmission alterations in cognitive and motor impairment in minimal hepatic encephalopathy. Neurochem. Int., 2015, 88, 15-19.
[http://dx.doi.org/10.1016/j.neuint.2014.10.011] [PMID: 25447766]
[6]
Hanlon, P.; Nicholl, B.I.; Jani, B.D.; Lee, D.; McQueenie, R.; Mair, F.S. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: A prospective analysis of 493 737 UK Biobank participants. Lancet Public Health, 2018, 3(7), e323-e332.
[http://dx.doi.org/10.1016/S2468-2667(18)30091-4] [PMID: 29908859]
[7]
Clegg, A.; Young, J.; Iliffe, S.; Rikkert, M.O.; Rockwood, K. Frailty in elderly people. Lancet, 2013, 381(9868), 752-762.
[http://dx.doi.org/10.1016/S0140-6736(12)62167-9] [PMID: 23395245]
[8]
Theou, O.; Cann, L.; Blodgett, J.; Wallace, L.M.; Brothers, T.D.; Rockwood, K. Modifications to the frailty phenotype criteria: Systematic review of the current literature and investigation of 262 frailty phenotypes in the survey of health, ageing, and retirement in Europe. Ageing Res. Rev., 2015, 21, 78-94.
[http://dx.doi.org/10.1016/j.arr.2015.04.001] [PMID: 25846451]
[9]
Fried, L.P.; Tangen, C.M.; Walston, J. Frailty in older adults: Evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci., 2001, 56(3), M146-M156.
[http://dx.doi.org/10.1093/gerona/56.3.M146] [PMID: 11253156]
[10]
Malaguarnera, M.; Vacante, M.; Frazzetto, P.M.; Motta, M. What is the frailty in elderly? value and significance of the multidimensional assessments. Arch. Gerontol. Geriatr., 2013, 56(1), 23-26.
[http://dx.doi.org/10.1016/j.archger.2011.09.017] [PMID: 23092818]
[11]
Cabrera-Pastor, A.; Malaguarnera, M.; Taoro-Gonzalez, L.; Llansola, M.; Felipo, V. Extracellular cGMP modulates learning biphasically by modulating glycine receptors, CaMKII and glutamate-nitric oxide-cGMP pathway. Sci. Rep., 2016, 6(1), 33124.
[http://dx.doi.org/10.1038/srep33124] [PMID: 27634333]
[12]
Acosta-Benito, M.A.; Sevilla-Machuca, I. Using prefrailty to detect early disability. J. Family Community Med., 2016, 23(3), 140-144.
[http://dx.doi.org/10.4103/2230-8229.189106] [PMID: 27625579]
[13]
Fhon, J.R.; Rodrigues, R.A.; Neira, W.F.; Huayta, V.M.; Robazzi, M.L. Fall and its association with the frailty syndrome in the elderly: Systematic review with meta-analysis. Rev. Esc. Enferm. USP, 2016, 50(6), 1005-1013.
[14]
Puts, M.T.E.; Toubasi, S.; Andrew, M.K. Interventions to prevent or reduce the level of frailty in community-dwelling older adults: A scoping review of the literature and international policies. Age Ageing, 2017, 46(3), 383-392.
[http://dx.doi.org/10.1093/ageing/afw247] [PMID: 28064173]
[15]
Ofori-Asenso, R.; Chin, K.L.; Mazidi, M. Global incidence of frailty and prefrailty among community-dwelling older adults: A systematic review and meta-analysis. JAMA Netw. Open, 2019, 2(8), e198398.
[http://dx.doi.org/10.1001/jamanetworkopen.2019.8398] [PMID: 31373653]
[16]
Calabrese, V.; Cornelius, C.; Stella, A.M.; Calabrese, E.J. Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: Role of hormesis and vitagenes. Neurochem. Res., 2010, 35(12), 1880-1915.
[http://dx.doi.org/10.1007/s11064-010-0307-z] [PMID: 21080068]
[17]
Umegaki, H.; Makino, T.; Uemura, K. Falls in community-dwelling prefrail older adults. Health Soc. Care Community, 2020, 28(1), 110-115.
[http://dx.doi.org/10.1111/hsc.12845] [PMID: 31476096]
[18]
Malaguarnera, G.; Catania, V.E.; Bonfiglio, C.; Bertino, G.; Vicari, E.; Malaguarnera, M. Carnitine serum levels in frail older subjects. Nutrients, 2020, 12(12), E3887.
[http://dx.doi.org/10.3390/nu12123887] [PMID: 33352627]
[19]
Malaguarnera, M.; Cauli, O. Effects of l-carnitine in patients with autism spectrum disorders: Review of clinical studies. Molecules, 2019, 24(23), 4262.
[http://dx.doi.org/10.3390/molecules24234262] [PMID: 31766743]
[20]
Norum, K.R.; Bremer, J. Acyl coenzyme A as an intermediate in the mitochondrial acylation of carnitine by α-keto acids BBA -. Biochim. Biophys. Acta, 1963, 78(1), 77-84.
[21]
Bremer, J. Carnitine in intermediary metabolism. The metabolism of fatty acid esters of carnitine by mitochondria. J. Biol. Chem., 1962, 237(12), 3628-3632.
[http://dx.doi.org/10.1016/S0021-9258(19)84498-8] [PMID: 14015219]
[22]
Malaguarnera, M.; Balzano, T.; Castro, M.C.; Llansola, M.; Felipo, V. The dual role of the GABAA receptor in peripheral inflammation and neuroinflammation: A study in hyperammonemic rats. Int. J. Mol. Sci., 2021, 22(13), 6772.
[http://dx.doi.org/10.3390/ijms22136772] [PMID: 34202516]
[23]
Maldonado, C.; Guevara, N.; Queijo, C.; González, R.; Fagiolino, P.; Vázquez, M. Carnitine and/or acetylcarnitine deficiency as a cause of higher levels of ammonia. BioMed Res. Int., 2016, 2016, 2920108.
[http://dx.doi.org/10.1155/2016/2920108] [PMID: 26998483]
[24]
Liu, J.; Ames, B.N. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer’s disease, and Parkinson’s disease. Nutr. Neurosci., 2005, 8(2), 67-89.
[http://dx.doi.org/10.1080/10284150500047161] [PMID: 16053240]
[25]
Badrasawi, M.; Shahar, S.; Zahara, A.M.; Nor Fadilah, R.; Singh, D.K. Efficacy of L-carnitine supplementation on frailty status and its biomarkers, nutritional status, and physical and cognitive function among prefrail older adults: A double-blind, randomized, placebo-controlled clinical trial. Clin. Interv. Aging, 2016, 11, 1675-1686.
[http://dx.doi.org/10.2147/CIA.S113287] [PMID: 27895474]
[26]
Pennisi, M.; Lanza, G.; Cantone, M. Acetyl-L-carnitine in dementia and other cognitive disorders: A critical update. Nutrients, 2020, 12(5), 1389.
[http://dx.doi.org/10.3390/nu12051389] [PMID: 32408706]
[27]
Crentsil, V. Mechanistic contribution of carnitine deficiency to geriatric frailty. Ageing Res. Rev., 2010, 9(3), 265-268.
[http://dx.doi.org/10.1016/j.arr.2010.02.005] [PMID: 20223299]
[28]
Malaguarnera, M. Acetyl-L-carnitine in hepatic encephalopathy. Metab. Brain Dis., 2013, 28(2), 193-199.
[http://dx.doi.org/10.1007/s11011-013-9376-4] [PMID: 23389620]
[29]
Liu, J.; Head, E.; Kuratsune, H.; Cotman, C.W.; Ames, B.N. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann. N. Y. Acad. Sci., 2004, 1033(1), 117-131.
[http://dx.doi.org/10.1196/annals.1320.011] [PMID: 15591009]
[30]
Mahoney, F.I.; Barthel, D.W. Functional evaluation: The barthel index. Md. State Med. J., 1965, 14, 61-65.
[PMID: 14258950]
[31]
Lawton, M.P.; Casten, R.; Parmelee, P.A.; Van Haitsma, K.; Corn, J.; Kleban, M.H. Psychometric characteristics of the minimum data set II: validity. J. Am. Geriatr. Soc., 1998, 46(6), 736-744.
[http://dx.doi.org/10.1111/j.1532-5415.1998.tb03809.x] [PMID: 9625190]
[32]
Malaguarnera, M.; Vacante, M.; Bertino, G. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin. J. Interferon Cytokine Res., 2011, 31(9), 653-659.
[http://dx.doi.org/10.1089/jir.2011.0010] [PMID: 21923249]
[33]
Choi, J.Y.; Yoon, S.J.; Kim, S.W. Prediction of postoperative complications using multidimensional frailty score in older female cancer patients with American Society of Anesthesiologists Physical Status Class 1 or 2. J. Am. Coll. Surg., 2015, 221(3), 652-60.e2.
[http://dx.doi.org/10.1016/j.jamcollsurg.2015.06.011] [PMID: 26232302]
[34]
Jamar: Hydraulic hand-held dynamometer. Available from: https://www.performancehealth.com/jamar-hydraulic-hand-dynamometer
[35]
Lycke, M.; Ketelaars, L.; Martens, E. The added value of an assessment of the patient’s hand grip strength to the comprehensive geriatric assessment in G8-abnormal older patients with cancer in routine practice. J. Geriatr. Oncol., 2019, 10(6), 931-936.
[http://dx.doi.org/10.1016/j.jgo.2019.01.001] [PMID: 30639266]
[36]
Rolland, Y.M.; Cesari, M.; Miller, M.E.; Penninx, B.W.; Atkinson, H.H.; Pahor, M. Reliability of the 400-m usual-pace walk test as an assessment of mobility limitation in older adults. J. Am. Geriatr. Soc., 2004, 52(6), 972-976.
[http://dx.doi.org/10.1111/j.1532-5415.2004.52267.x] [PMID: 15161464]
[37]
Cabrera-Pastor, A.; Llansola, M.; Montoliu, C. Peripheral inflammation induces neuroinflammation that alters neurotransmission and cognitive and motor function in hepatic encephalopathy: Underlying mechanisms and therapeutic implications. Acta Physiol., 2019, 226(2), e13270.
[http://dx.doi.org/10.1111/apha.13270] [PMID: 30830722]
[38]
Bruno, C.M.; Sciacca, C.; Cilio, D.; Bertino, G.; Pellicano, R. Erythropoietin in liver cirrhosis: Two questions without answers. World J. Gastroenterol., 2005, 11(23), 3649.
[http://dx.doi.org/10.3748/wjg.v11.i23.3649] [PMID: 15962396]
[39]
Cederblad, G.; Lindstedt, S. A method for the determination of carnitine in the picomole range. Clin. Chim. Acta, 1972, 37, 235-243.
[http://dx.doi.org/10.1016/0009-8981(72)90438-X] [PMID: 5022087]
[40]
Wall, B.T.; Stephens, F.B.; Constantin-Teodosiu, D.; Marimuthu, K.; Macdonald, I.A.; Greenhaff, P.L. Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans. J. Physiol., 2011, 589(Pt 4), 963-973.
[http://dx.doi.org/10.1113/jphysiol.2010.201343] [PMID: 21224234]
[41]
Malaguarnera, G.; Catania, V.E.; Bertino, G. Serum Folate deficiency in HCV related hepatocellular carcinoma. Sci. Rep., 2022, 12(1), 5025.
[http://dx.doi.org/10.1038/s41598-022-09030-1] [PMID: 35322130]
[42]
Jones, L.L.; McDonald, D.A.; Borum, P.R. Acylcarnitines: Role in brain. Prog. Lipid Res., 2010, 49(1), 61-75.
[http://dx.doi.org/10.1016/j.plipres.2009.08.004] [PMID: 19720082]
[43]
Nasca, C.; Xenos, D.; Barone, Y. L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc. Natl. Acad. Sci. USA, 2013, 110(12), 4804-4809.
[http://dx.doi.org/10.1073/pnas.1216100110] [PMID: 23382250]
[44]
Kobayashi, S.; Iwamoto, M.; Kon, K.; Waki, H.; Ando, S.; Tanaka, Y. Acetyl-L-carnitine improves aged brain function. Geriatr. Gerontol. Int., 2010, 10(Suppl. 1), S99-S106.
[http://dx.doi.org/10.1111/j.1447-0594.2010.00595.x] [PMID: 20590847]
[45]
White, H.L.; Scates, P.W. Acetyl-L-carnitine as a precursor of acetylcholine. Neurochem. Res., 1990, 15(6), 597-601.
[http://dx.doi.org/10.1007/BF00973749] [PMID: 2215852]
[46]
Malaguarnera, G.; Vacante, M.; Drago, F. Endozepine-4 levels are increased in hepatic coma. World J. Gastroenterol., 2015, 21(30), 9103-9110.
[http://dx.doi.org/10.3748/wjg.v21.i30.9103] [PMID: 26290636]
[47]
Vecchio, M.; Malaguarnera, G.; Giordano, M. A musician’s dystonia. Lancet, 2012, 379(9831), 2116.
[http://dx.doi.org/10.1016/S0140-6736(12)60315-8] [PMID: 22656885]
[48]
Galvano, F.; Li Volti, G.; Malaguarnera, M. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin. Pharmacother., 2009, 10(12), 1875-1882.
[http://dx.doi.org/10.1517/14656560903081745] [PMID: 19618992]
[49]
Rooks, D.; Praestgaard, J.; Hariry, S. Treatment of sarcopenia with bimagrumab: Results from a Phase II, randomized, controlled, proof-of-concept study. J. Am. Geriatr. Soc., 2017, 65(9), 1988-1995.
[http://dx.doi.org/10.1111/jgs.14927] [PMID: 28653345]
[50]
Cabrera-Pastor, A.; Balzano, T.; Hernández-Rabaza, V.; Malaguarnera, M.; Llansola, M.; Felipo, V. Increasing extracellular cGMP in cerebellum in vivo reduces neuroinflammation, GABAergic tone and motor in-coordination in hyperammonemic rats. Brain Behav. Immun., 2018, 69, 386-398.
[http://dx.doi.org/10.1016/j.bbi.2017.12.013] [PMID: 29288802]
[51]
Fielding, R.; Riede, L.; Lugo, J.P.; Bellamine, A. l-Carnitine supplementation in recovery after exercise. Nutrients, 2018, 10(3), 349.
[http://dx.doi.org/10.3390/nu10030349] [PMID: 29534031]
[52]
Varney, J.L.; Fowler, J.W.; Gilbert, W.C.; Coon, C.N. Utilisation of supplemented l-carnitine for fuel efficiency, as an antioxidant, and for muscle recovery in Labrador retrievers. J. Nutr. Sci., 2017, 6, e8.
[http://dx.doi.org/10.1017/jns.2017.4] [PMID: 28620483]
[53]
Barhwal, K.; Singh, S.B.; Hota, S.K.; Jayalakshmi, K.; Ilavazhagan, G. Acetyl-L-carnitine ameliorates hypobaric hypoxic impairment and spatial memory deficits in rats. Eur. J. Pharmacol., 2007, 570(1-3), 97-107.
[http://dx.doi.org/10.1016/j.ejphar.2007.05.063] [PMID: 17610872]
[54]
Famularo, G.; De Simone, C.; Trinchieri, V.; Mosca, L. Carnitines and its congeners: A metabolic pathway to the regulation of immune response and inflammation. Ann. N. Y. Acad. Sci., 2004, 1033(1), 132-138.
[http://dx.doi.org/10.1196/annals.1320.012] [PMID: 15591010]
[55]
Quillet-Mary, A.; Jaffrézou, J.P.; Mansat, V.; Bordier, C.; Naval, J.; Laurent, G. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J. Biol. Chem., 1997, 272(34), 21388-21395.
[http://dx.doi.org/10.1074/jbc.272.34.21388] [PMID: 9261153]
[56]
Singhai, A.; Yadav, V.; Jha, R.K. Effect of L-carnitine supplementation on inflammatory marker of coronary artery disease. Int J Adv Med, 2017, 4(2), 467-470.
[http://dx.doi.org/10.18203/2349-3933.ijam20171043]
[57]
Lee, B.J.; Lin, J.S.; Lin, Y.C.; Lin, P.T. Antiinflammatory effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients. Nutrition, 2015, 31(3), 475-479.
[http://dx.doi.org/10.1016/j.nut.2014.10.001] [PMID: 25701337]
[58]
Vecchio, M.; Chiaramonte, R.; Testa, G.; Pavone, V. Clinical effects of L-carnitine supplementation on physical performance in healthy subjects, the key to success in rehabilitation: A systematic review and meta-analysis from the rehabilitation point of view. J. Funct. Morphol. Kinesiol., 2021, 6(4), 93.
[http://dx.doi.org/10.3390/jfmk6040093] [PMID: 34842765]
[59]
Galvano, F.; Malaguarnera, M.; Vacante, M. The physiopathology of lipoprotein (a). Front. Biosci. (Schol. Ed.), 2010, 2(3), 866-875.
[http://dx.doi.org/10.2741/s107] [PMID: 20515830]
[60]
Vidal-Casariego, A.; Burgos-Peláez, R.; Martínez-Faedo, C. Metabolic effects of L-carnitine on type 2 diabetes mellitus: Systematic review and meta-analysis. Exp. Clin. Endocrinol. Diabetes, 2013, 121(4), 234-238.
[http://dx.doi.org/10.1055/s-0033-1333688] [PMID: 23430574]
[61]
Malaguarnera, G.; Pennisi, M.; Gagliano, C. Acetyl-L-carnitine supplementation during HCV therapy with pegylated interferon-α 2b plus ribavirin: Effect on work performance; A randomized clinical trial. Hepat. Mon., 2014, 14(5), e11608.
[http://dx.doi.org/10.5812/hepatmon.11608] [PMID: 24910702]
[62]
Malaguarnera, M.; Vacante, M.; Motta, M.; Malaguarnera, M.; Li Volti, G.; Galvano, F. Effect of L-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. Metabolism, 2009, 58(11), 1618-1623.
[http://dx.doi.org/10.1016/j.metabol.2009.05.014] [PMID: 19604523]
[63]
Rebouche, C.J. Carnitine function and requirements during the life cycle. FASEB J., 1992, 6(15), 3379-3386.
[http://dx.doi.org/10.1096/fasebj.6.15.1464372] [PMID: 1464372]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy